Amarin Technologies S.A. has research and development capabilities, which allow the Company to perform and control all aspects of the product development process. An experienced team coordinates and manages all of the Company's research, project planning and product development programs. The Company performs an exhaustive pharmaceutical, medical and IP analysis of the agents selected before beginning the pharmaceutical development.

Amarin possesses modern formulation and analytical laboratories, which work following GMP and cGLP guidelines. Their premises include a full coating and drying unit for the manufacture of drug-in-adhesive transdermal systems under pilot batches or biobatch scales.

The pre-clinical studies (e.g. primary irritation, sensitization and pharmacokinetics in animals) are carried out following cGLP guidelines, in third-party facilities.

Amarin also performs clinical studies by means of properly designed protocols in order to evaluate pharmacokinetics, efficacy and safety of the products under development. All studies are closely supervised by certified clinical monitors and physicians, following quality policies and SOPs.